medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2003, Number 6

<< Back Next >>

Rev Mex Oftalmol 2003; 77 (6)

Estudio comparativo entre prednisolona y rimexolona en pacientes con uveítis anterior HLA-B27 positivos

Padilla-Aguilar G, Arellanes-García L, Navarro-López P, Espinoza-Martínez C

Language: Spanish
References: 12
Page: 228-231
PDF size: 156.68 Kb.


ABSTRACT

Purpose: To compare the efficacy of prednisolone acetate 1% and 1% rimexolone ophthalmic suspension in the treatment of acute anterior uveitis (AAU) in HLA-B27 + patients.
Methods: Sixty-eight AAU HLA-B27+ patients were randomly selected for treatment with prednisolone acetate 1% (Group A) or rimexolone 1% (Group B). All patients showed mild to moderate anterior chamber inflammation. It was a prospective, randomized, double blind, clinical trial
Results: There was no a statistically significant difference among A and B groups when anterior chamber flare and cells were measured.
Conclusion: Rimexolone 1% is as effective as prednisolone acetate 1% in the treatment of mild to moderate AAU HLAB27 +. Final IOP in both groups was similar.


REFERENCES

  1. Friedlaender MH. Corticosteroid therapy of ocular inflammation. Int Ophthalmol 1983:23,175-182.

  2. Leopold IH, Gaster RN. Ocular inflamation and antiinflamatory drugs. En: Kaufman HE, McDonald MB, Barron BA, Waltman SR (eds.). The cornea. Nueva York, Churchill Livingstone; 1988:67-84

  3. Fingeret M, Potter JW, Bartlettt JD, Jaanus SD. Uveitis. En: Clinical Ocular Pharmacology. Boston, Butterworth Publisehrs; 1989:623-638.

  4. Foster S, Alter G, DeBarge R, Raizman M, Crabb J, Santos C, Feiler S, Frielaender H. Efficacy and safety of Rimexolona 1% ophthalmic suspension vs. 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 1996; 122:171-182.

  5. Assil K, Massry G, Lehmann R, Fox K, Stewart R. Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. J Cataract Refract Sur, 1997; 23:750-57.

  6. Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis: I. Anterior uveitis. Am J Opthalmol 1959; 47: 155-170.

  7. Kimura S. Sign and symptoms of uveitis : II. Classification of the posterior manifestations of uveitis. Am J Ophtalmol 1959; 47:171-176.6.

  8. Armaly MF. Effects of corticosteroid on intraocular pressure and fluid dynamics: The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963; 70:482-491.

  9. Mindel JS, Tavitian HO, Smth H Jr, Walker EC. Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol 1980; 98:1577-1578.

  10. Rosenbaum JT. HLA B27 – Associated Disease. En: Pepose JS, Holland GN, Wilhelmus KR (eds.). Ocular Infection and Immunity. St. Louis, Mosby-Year Book, 1996: 475-484.

  11. Mindel JS, Goldberg J, Tavitian HO. Similarity of the intraocular pressure response to different corticosteroids esters when compliance is controlled. Ophthalmol 1979; 86:99-107.

  12. Frangie JP, Leibowitz HM. Steroids. Int Ophthalmol Clin 1993; 33(4): 9-29.




2020     |     www.medigraphic.com